Breaking the Bottleneck: Dedicated MicroED Rewrites Pharma R&D Rules

SUZHOU, China – November 04, 2026 — For decades, pharmaceutical development has been held hostage by a fundamental law of physics: to understand the three-dimensional structure of a molecule using traditional X-ray crystallography, scientists first had to grow a sufficiently large, flawless single crystal. This tedious, unpredictable process has long been a notorious bottleneck in drug discovery, occasionally stalling critical pipeline assets for weeks or months. Today, that paradigm is shifting rapidly as purpose-built electron diffraction technology moves from the fringes of academic research into the industrialized core of global contract research.

Crystal Pharmatech, a science-driven contract research and development organization specializing in small-molecule solid-state research, announced the successful installation and routine operation of the ELDICO ED-1 electron diffractometer at its Suzhou R&D center. The deployment marks the first industrial-grade electron diffractometer installed in the Asia-Pacific region, signaling a broader strategic arms race among global contract research organizations (CROs) to offer structurally definitive data at unprecedented speeds.

Overcoming the Single-Crystal Hurdle

The transition from traditional Single Crystal X-ray Diffraction (SCXRD) to Microcrystal Electron Diffraction (MicroED) represents a leap in analytical capability. While X-ray photons interact relatively weakly with matter, requiring a large crystalline lattice to produce a usable diffraction pattern, electrons interact with matter up to 100,000 times more strongly. This intense interaction allows researchers to extract high-resolution diffraction data from nano- to micro-sized crystals—samples that would be invisible to conventional X-ray techniques.

Crystal Pharmatech has been utilizing MicroED since 2021, previously relying on repurposed cryo-electron microscopes (cryo-EM) to collect data. However, adapting general-purpose transmission electron microscopes for diffraction experiments often required specialized expertise and complex workflows to mitigate beam damage to fragile organic molecules.

The introduction of the ELDICO ED-1 changes this dynamic. Designed specifically for small-molecule crystals, the instrument features a horizontal beam path, a 5-axis goniometer, and a DECTRIS QUADRO hybrid pixel detector. By utilizing an optimized electron beam source and optical column designed to minimize sample degradation, the system is built purely for diffraction.

"Five years after launching MicroED on a cryo-EM instrument, we now have a dedicated, automated electron diffractometer in our own laboratory," said Dr. Alex Chen, Co-founder, Chairman and CEO of Crystal Pharmatech. "It was collecting data within three days of installation, and I can already see it becoming a workhorse for our solid-state research. Clients can now ask for the structure of each form a screen finds, quickly and on very little material."

De-Risking Intellectual Property on a Milligram Scale

In the high-stakes landscape of 2026 pharmaceutical strategy, the ability to rapidly determine crystal structures is not merely an analytical convenience; it is a critical instrument for intellectual property defense and regulatory compliance.

Drug substances frequently exist in multiple crystalline forms, known as polymorphs, each possessing distinct physical properties that can drastically alter a drug's stability, bioavailability, and manufacturability. Historically, late-stage polymorph surprises have forced costly drug reformulations and triggered complex patent disputes. Regulatory bodies demand rigorous solid-state characterization to ensure the consistency and safety of the final drug product.

By integrating dedicated MicroED directly into routine solid-form screening, researchers can now identify hydrates, solvates, salts, cocrystals, and individual phases in complex mixtures using sub-micron powders from sample quantities as small as one milligram. This bypasses the need to grow large single crystals entirely.

Pharmaceutical patent attorneys and regulatory officers note that mapping structurally resolved polymorph landscapes early in development significantly de-risks pipeline assets. When developers can definitively prove the absolute configuration of every polymorph a screen identifies, they lock down their intellectual property and prevent late-stage manufacturing crises. Crystal Pharmatech is pushing this advantage aggressively, offering standard turnaround times of one to two weeks, and an expedited service delivering analysis in as little as 48 hours under a "No Structure, No Fee" commitment.

Instrumenting the Asia-Pacific CRO Boom

The installation of the ED-1 in Suzhou also highlights a macro trend in the globalization of pharmaceutical research. The Asia-Pacific region, particularly China, has cemented its position as a powerhouse for contract research and manufacturing. To capture high-value contracts from Western biotechnology and pharmaceutical companies, APAC-based CROs are heavily investing in top-tier, next-generation analytical hardware.

Swiss technology manufacturer ELDICO Scientific AG, the developer of the ED-1, is capitalizing on this demand. While other CROs globally—such as Triclinic Labs, Holodiag, and Ardena—have recently integrated ELDICO's technology into their workflows, Crystal Pharmatech's acquisition establishes a crucial foothold for dedicated MicroED in the Asian market.

The commercial advantage of bringing this capability in-house is substantial. Contract labs are no longer competing solely on cost arbitrage; they are competing on technological superiority and speed. By placing the ED-1 directly beside its screening and crystallization teams, Crystal Pharmatech has transformed MicroED from an exotic, outsourced experiment into a routine, automated step in solid-form selection.

"We're pleased to see the ED-1 in service at Crystal Pharmatech. Their team brings extensive experience in solid form research, and the instrument's automated operation makes it easier to include crystal structure determination in their everyday screening work," said Dr. James Berwick, CEO of ELDICO Scientific AG. "This is exactly how we intended the ED-1 to be used, helping scientists make informed decisions during pharmaceutical development."

A New Standard for Solid-State Research

The industrialization of electron diffraction is accelerating across the sector. While competitors like Rigaku and JEOL have collaborated on integrated platforms like the XtaLAB Synergy-ED, and Thermo Fisher continues to advance cryo-TEM applications for MicroED, the shift toward dedicated, user-friendly diffractometers signals that the technology is maturing. The focus is no longer on proving that electron diffraction works, but on how seamlessly it can be integrated into high-throughput, 24/7 industrial workflows.

The broader implications of this technological maturation will be on display at Crystal Pharmatech’s upcoming Boston Symposium, "First Time Right," scheduled for November 19, 2026. The event will feature data benchmarking the probability of electron diffraction success on routine polymorph screening isolates across various solid-form categories, presented alongside experts from ELDICO Scientific AG, including Co-founder Gustavo Santiso-Quiñones, Ph.D.

As the pharmaceutical industry continues to tackle increasingly complex molecules—from targeted protein degraders like PROTACs to oral cyclic peptides—the margin for error in solid-state formulation is shrinking. The ability to peer into the atomic structure of a sub-micron powder within 48 hours is rapidly transitioning from a competitive advantage to a baseline requirement. For companies navigating the intricate pathways of modern drug development, dedicated MicroED is illuminating the microscopic details that ultimately drive macroscopic global value.